Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme (2021)
Attributed to:
CANCER: Trials with potential global reach and other challenging trials
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Type: Journal Article/Review
Volume: 397
Parent Publication: LANCET
Issue: 10274
ISSN: 0140-6736